Silgan Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q3 adjusted EPS rose 7% to $1.31, with adjusted EBIT up 6% despite uneven consumer demand and inflation. FY 2026 EPS guidance increased; 2027 organic earnings and free cash flow growth are expected.
-
The Trivium deal forms a scaled global metal-packaging platform with $225M of targeted synergies over three years. AIP funding is designed to keep the transaction leverage-neutral while preserving investment flexibility and a potential tax-free separation.
-
Q2 2026 saw 7% sales growth and solid execution despite inflation and market volatility, with strong pet food and fragrance performance offsetting softness in Brazil and human food. Guidance for 2026 EPS and free cash flow was reaffirmed, with volume growth expected across all segments.
-
Q1 2026 results exceeded expectations with strong growth in fragrance/beauty and pet food, offsetting weather and inflation headwinds. 2026 guidance was raised, driven by operational outperformance, new wins, and robust free cash flow outlook.
Fiscal Year 2025
-
Delivered strong 2025 results with record performance in Dispensing and Specialty Closures and Metal Containers, driven by pet food and fragrance/beauty growth. 2026 guidance calls for continued EBIT and EBITDA growth, with free cash flow of $450 million and CapEx focused on dispensing and pet food.
-
Q3 saw 15% sales growth and strong segment performance, led by dispensing products and pet food. Guidance for Q4 and 2025 reflects lower personal/home care volumes and higher interest/tax, but free cash flow and deleveraging targets remain on track.
-
Q2 delivered record Adjusted EBIT and 15% Adjusted EPS growth, driven by dispensing and pet food markets, with strong Weener integration and cost reductions. 2025 guidance revised for $20M EBIT headwinds from weather and a customer bankruptcy, but core growth outlook remains robust.
-
Record Q1 results with 11% sales and 19% adjusted EPS growth, driven by organic gains and the Weener acquisition. 2025 guidance reaffirmed, with mid-single-digit volume growth expected across all segments and strong free cash flow outlook.
Fiscal Year 2024
-
Strong 2024 results featured record segment performance, double-digit free cash flow growth, and successful integration of Weener Plastics. 2025 guidance calls for double-digit earnings and cash flow growth, driven by organic initiatives, cost savings, and segment momentum.
-
Q3 saw resilient performance with strong growth in dispensing and custom containers, but metal containers were impacted by historically low fruit and vegetable pack volumes. The Weener acquisition is expected to drive future growth, with 2024 EPS guidance raised and double-digit EPS growth targeted for 2025.
-
Q2 2024 saw strong adjusted EPS growth, improved volumes, and robust segment performance, with guidance for full-year EPS and free cash flow reaffirmed. The Weener Packaging acquisition is set to boost margins and growth, while demand normalization and targeted investments support a positive outlook.
-
The acquisition of Weener Plastics strengthens the buyer's leadership in dispensing and specialty closures, adding high-margin, innovative products and expanding exposure to healthcare and personal care markets. The EUR 838 million deal is expected to deliver 10% EPS accretion post-synergy, with EUR 20 million in cost savings and a fully synergized EBITDA margin of 26%.